Editorial for “T1 Mapping on Gd‐EOB‐DTPA‐Enhanced MRI for the Prediction of Oxaliplatin‐Induced Liver Injury in a Mouse Model”

Li Yang,Ying Ding,Shengxiang Rao,Caizhong Chen,Mengsu Zeng

DOI: https://doi.org/10.1002/jmri.27377

IF: 4.4

2020-01-01

Journal of Magnetic Resonance Imaging

Abstract:Editorial for “T1 Mapping on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Oxaliplatin-Induced Liver Injury in a Mouse Model” Oxaliplatin (OXA) is a third-generation platinum commonly used antitumor drug and is used in the treatment of gastrointestinal cancers. The most common use is seen in colorectal cancers followed by the gastric, liver, and pancreatic cancers. OXA is a cisplatin derivative and has less renal toxicity compared with cisplatin. However, there are many studies showing significant damage to nontumor-bearing liver. This damage evaluation is now being done by a T1 mapping of the gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) contrast study by magnetic resonance imaging (MRI). This is a newer, novel concept for risk assessment and injury evaluation being done in a mouse model. The results show significant potential for liver injury evaluation. OXA is more a commonly used antitumor drug for various cancers in mouse models. This chemotherapeutic agent has involved many studies for various grades of the hepatic injury in the normal liver. The most common presentation is so-called sinusoidal obstruction syndrome (SOS). SOS is significantly characterized by obliteration and dilatation of the liver sinusoids due to collagenization of the perisinusoidal space. This is due to erythrocyte extravasation and hepatocyte plate disruption. These changes can cause inhibition of future remnant liver hypertrophy following portal vein embolization, increased risk of intraoperative bleeding and transfusion rate, intrahepatic sinus platelet aggregation, hepatocyte atrophy and necrosis, hepatic steatosis, steatohepatitis, intrahepatic sinus haemorrhage, and sinusoidal obstruction syndrome hepatomegaly with pain, splenomegaly, ascites, hepatic vein narrowing (HVN), and gall bladder wall thickening and an increased rate of liver insufficiency and ultimately may lead to hepatectomy. In the early form this can be misinterpreted as metastases. Thus, early diagnosis of SOS by imaging is important for the management of patients prior to surgery and during follow-up. These changes are difficult to evaluate by routine imaging. Gd-EOB-DTPA is a commonly used MR contrast agent for T1weighted images. 6 After intravenous injection, Gd-EOB-DTPA is cleared by biliary excretion and renal excretion. Gd-EOB DTPA is taken up by hepatocytes and excreted via the biliary pathway. In this issue, Yang et al, report that GdEOB-DTPA has a T1-shortening effect, so the measurement of the T1 relaxation time of liver parenchyma before and after GdEOB-DTPA administration allows quantitative evaluation of Gd-EOB-DTPA uptake by the liver parenchyma, thus reflecting liver function. Thus, with this same concept, it was described in a mouse model of the efficacy of this contrast agent. Organic anion-transporting polypeptide (OATP) is known to mediate the uptake of Gd-EOB-DTPA by hepatocytes and multidrug resistance protein (MRP), which further mediates biliary excretion of Gd-EOBDTPA. Reduced reduction rates of T1 relaxation time in liver fibrosis may be explained by a hypofunction of OATP and fewer normalfunctioning hepatocytes. After Gd-EOB-DTPA injection, the beginning of the hepatocyte uptake could be identified at 1.5 minutes and 50% of the administered dose was transported into the hepatocytes at 20 minutes. Therefore, the imaging at 20 minutes after Gd-EOB-DTPA injection was used as a “standard” hepatobiliary phase (HBP) to assess liver lesions and function. The HBP imaging obtained at 10 minutes is a feasible timepoint for replacing 20-minute HBP imaging after Gd-EOB-DTPA injection to diagnose liver lesion with a 3.0T MRI system. The reason here is that the MRI signal-to-noise ratio (SNR) can be expected to increase by twofold at 3.0T than 1.5T, and the contrast-to noise ratio (CNR) also would be improved. The mouse model study shows liver function and injury after OXA therapy. This shows the significant importance of the T1 mapping in the successful evaluation of liver injury. This again will be able to differentiate from metastases, also especially in the early stages.